Sugi Predict

Sugi Predict / Compounds / SCHEMBL416899

SCHEMBL416899

SCHEMBL416899

Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.78
▸ FABP6 P51161 1/20 0.78
▸ ALDH1A1 P00352 4/20 0.54
▸ HPGD P15428 3/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MASP2 O00187 1/20 0.50
▸ NUDT1 P36639 1/20 0.50
▸ AOC3 Q16853 1/20 0.50
▸ HTT P42858 3/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ CHEK2 O96017 1/20 0.48
▸ SCD O00767 1/20 0.48
▸ PBRM1 Q86U86 1/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ XIAP P98170 1/20 0.46
▸ ABCC4 O15439 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL16324631 0.98 ABL1 (0.76) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL3499235 0.88 ABL1 (1.00) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL29575638 0.88 ABL1 (1.00) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL11543362 0.87 ABL1 (0.59) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL26075185 0.87 FABP6 (0.59) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL1870891 0.84 FABP6 (0.55) ABL1FABP6ALDH1A1HPGDRAB9A
Hydrochloric Acid SCHEMBL4682527 0.83 FABP6 (0.54) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL416898 0.82 ABL1 (0.55) ABL1FABP6ALDH1A1HPGDRAB9A
Bromide SCHEMBL16324207 0.82 ABL1 (0.54) ABL1FABP6ALDH1A1HPGDRAB9A
SCHEMBL10466050 0.82 ALDH1A1 (0.54) ABL1FABP6ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108828110-B Method for determining residual quantity of benzimidazole drugs in chicken fat 广东出入境检验检疫局检验检疫技术中心 2021-09-21 — — CN claimed
CN-108519453-B Isotope dilution-editable multi-reaction monitoring mode-based 19-benzimidazole-drug residual quantity determination method 广东出入境检验检疫局检验检疫技术中心 2021-09-21 — — CN claimed
CN-109001334-B Method for measuring residual quantity of benzimidazole drugs in chicken tissues 广东出入境检验检疫局检验检疫技术中心 2021-04-27 — — CN claimed
CN-109001334-A The measuring method of benzimidazoles residues residual quantity in a kind of chicken tissues 广东出入境检验检疫局检验检疫技术中心 2018-12-14 — — CN claimed
CN-108828110-A The measuring method of benzimidazoles residues residual quantity in one breeder fat 广东出入境检验检疫局检验检疫技术中心 2018-11-16 — — CN claimed
CN-121647264-A Application of 2-amino-5-benzoyl benzimidazole in preventing and treating wheat powdery mildew and promoting wheat growth 河南省农业科学院植物保护研究所 2026-03-13 — — CN disclosed
CN-121647264-A Application of 2-amino-5-benzoyl benzimidazole in preventing and treating wheat powdery mildew and promoting wheat growth 河南省农业科学院植物保护研究所 2026-03-13 — — CN disclosed
US-20240115552-A1 MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS THE JOHNS HOPKINS UNIVERSITY 2024-04-11 — — US disclosed
EP-3253384-B1 MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS UNIV JOHNS HOPKINS (US) 2021-12-15 — — EP disclosed
US-20210369679-A1 MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS THE JOHNS HOPKINS UNIVERSITY (US) 2021-12-02 — — US disclosed
CN-108519453-B Isotope dilution-editable multi-reaction monitoring mode-based 19-benzimidazole-drug residual quantity determination method 广东出入境检验检疫局检验检疫技术中心 2021-09-21 — — CN disclosed
CN-108828110-B Method for determining residual quantity of benzimidazole drugs in chicken fat 广东出入境检验检疫局检验检疫技术中心 2021-09-21 — — CN disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 — — US disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 — — EP disclosed
US-20080070303-A1 Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement ADVANCED CELL TECHNOLOGY 2008-03-20 — — US disclosed
WO-2007062198-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECHNOLOGY, INC. (US) 2007-05-31 — — WO disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 — — WO disclosed
US-20060247253-A1 Novel heterocyclic NF-kB inhibitors 4 SC AG (DE) 2006-11-02 — — US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
US-4167569-A ANTICOAGULANTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247253-A1 Novel heterocyclic NF-kB inhibitors NFKBIA, NFRKB, NFKB2 ABL1 1877/4885FABP6 3983/4885ALDH1A1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.